Modular Biopharmaceutical Manufacturing Network for Flexible Small Batches
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The biopharmaceutical industry faces challenges in efficiently manufacturing complex and small-volume biologic medicines, such as vaccines and personalized drugs, due to the need for highly specialized and flexible production processes, which often result in increased costs, environmental impact, and complexity in managing production volumes and equipment usage.
Innovation Solution
A manufacturing system comprising a macro structure with a warehouse facility, hydration facility, and multiple self-sufficient and inter-operationally discrete micro nodes connected via a network spine, allowing for independent operation, improved resource utilization, and automated material transport, while maintaining quality assurance and reducing environmental impact.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If highly specialized and flexible production processes are used for small-volume biologic medicines, then manufacturing quality and adaptability are improved, but production costs and operational complexity increase
Solution Approach 1:
The manufacturing system is divided into multiple independent production modules, each capable of handling specific biologic medicine production tasks. These modular units can be independently configured and operated, providing flexibility for different product types while simplifying individual module design and operation.
Solution Approach 2:
The production modules are designed with universal capabilities to handle multiple types of biologic medicines through reconfigurable processes and equipment. This multi-functionality allows the same modular infrastructure to support diverse manufacturing needs without requiring entirely separate specialized facilities for each product type.
2Adaptability or versatility
If highly specialized and flexible production processes are used for small-volume biologic medicines, then manufacturing quality and adaptability are improved, but capital and operating costs increase
Solution Approach 1:
By segmenting the manufacturing system into reusable modular units, capital costs are distributed across multiple configurable modules rather than requiring entirely specialized facilities for each product. This reduces overall capital expenditure while maintaining flexibility through modular reconfiguration.
Solution Approach 2:
The system enables cost-effective adaptation through parameter changes in modular configurations rather than requiring complete redesigns. Process parameters, equipment settings, and module arrangements can be adjusted to accommodate different biologic medicines, providing flexibility without proportional increases in manufacturing costs.
3Manufacturing precision
If production processes are optimized for small volumes, then product specificity is improved, but equipment utilization efficiency and volume management become more difficult
Solution Approach 1:
Multiple independent production modules allow simultaneous operation on different product lines, improving overall equipment utilization. Each module can be optimized for specific product requirements while the aggregate system maintains high productivity through parallel processing of multiple small-volume batches.
Solution Approach 2:
The system dynamically allocates production capacity across modular units based on real-time demand and product requirements. This dynamic configuration enables optimal equipment utilization by flexibly assigning modules to different products and adjusting production volumes, maintaining both specificity and efficiency.
4Adaptability or versatility
If frequent changeovers and equipment reconfigurations are performed to accommodate product variety, then manufacturing flexibility is improved, but production time and operational complexity increase
Solution Approach 1:
Modular production modules are designed for rapid reconfiguration between products, minimizing changeover time. Each module can be independently adjusted or replaced, allowing quick transitions between different biologic medicines without requiring extensive system-wide reconfigurations.
Solution Approach 2:
Modules are pre-configured with standardized interfaces and components that enable rapid changeovers. Cleaning protocols, tooling setups, and process parameters are prepared in advance for different product types, reducing the time and complexity associated with frequent reconfigurations to accommodate product variety.
Data Source
AI summary
The present disclosure relates to a manufacturing system, method and control circuitry for quality assured manufacturing of at least two biopharmaceutical products. The manufacturing system comprises a warehouse facility, a hydration facility, and at least two biopharmaceutical manufacturing facilities, wherein the warehouse facility and hydration facility are comprised in the macro structure. Each biopharmaceutical manufacturing facility is comprised in a respective micro node, and a control facility in the macro structure is configured to control interoperability of the macro structure and the micro nodes by means of a network spine interconnecting the macro structure with each micro node.